| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Lysine clonixinate targets cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By inhibiting COX enzymes, it reduces the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever. It is a non-selective COX inhibitor.
|
|---|---|
| ln Vitro |
In vitro, lysine clonixinate inhibits COX-1 and COX-2 enzyme activity. It reduces prostaglandin synthesis in various cell types. The compound shows anti-inflammatory activity in standard in vitro assays. The lysine salt form provides improved solubility compared to the parent compound.
|
| ln Vivo |
In vivo, lysine clonixinate has analgesic, anti-inflammatory, and antipyretic effects. It is used clinically for the treatment of pain and inflammation. The lysine salt provides faster onset of action due to improved solubility and absorption.
|
| Enzyme Assay |
Non-cellular enzyme assays for lysine clonixinate involve measuring COX-1 and COX-2 inhibition. The enzymes are incubated with arachidonic acid (substrate) and varying concentrations of the compound. Prostaglandin production is measured by ELISA or other methods. IC₅₀ values are calculated.
|
| Cell Assay |
In vitro cellular experiments involve culturing cells that express COX enzymes (e.g., macrophages). Cells are stimulated with LPS to induce COX-2 expression and prostaglandin production. Lysine clonixinate is added at various concentrations, and prostaglandin levels are measured by ELISA.
|
| Animal Protocol |
In vivo animal studies include standard models of inflammation, pain, and fever. Carrageenan-induced paw edema is used for anti-inflammatory assessment. The hot plate test or formalin test is used for analgesic evaluation. The compound is administered orally or parenterally.
|
| ADME/Pharmacokinetics |
Lysine clonixinate is rapidly absorbed after oral administration due to the improved solubility of the lysine salt. It is metabolized in the liver and excreted through the kidneys. The compound has a half-life suitable for multiple daily dosing.
|
| Toxicity/Toxicokinetics |
Lysine clonixinate, like other NSAIDs, may cause gastrointestinal effects including dyspepsia, nausea, and ulceration. It may also affect renal function and platelet aggregation. The compound should be used with caution in patients with a history of gastrointestinal bleeding or renal impairment.
|
| Additional Infomation |
Clonixin lysine salt is an organic ammonium salt composed of clonixin and an equimolar amount of L-lysine. It is used to treat renal colic, muscle pain, and moderate migraine attacks. It has vasodilatory, platelet aggregation inhibitory, nonsteroidal anti-inflammatory, non-narcotic analgesic, antipyretic, EC 1.14.99.1 (prostaglandin intraperoxidase) inhibitor, and lipoxygenase inhibitor effects. It contains L-lysine (1+) and clonixin (1-).
Lysine clonixinate is the lysine salt of clonixin, a non-selective COX inhibitor used for its analgesic, anti-inflammatory, and antipyretic properties. The lysine salt improves solubility and bioavailability, providing faster onset of action. This product is for research purposes only and is not for human therapeutic use. |
| Molecular Formula |
C19H25CLN4O4
|
|---|---|
| Molecular Weight |
408.88
|
| Exact Mass |
408.156
|
| CAS # |
55837-30-4
|
| PubChem CID |
3080836
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.386g/cm3
|
| Boiling Point |
410.2ºC at 760 mmHg
|
| Melting Point |
208-214ºC (dec.)
|
| Flash Point |
201.9ºC
|
| LogP |
4.486
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
28
|
| Complexity |
407
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=C(C=CC=C1NC2=C(C=CC=N2)C(=O)O)Cl.C(CCN)C[C@@H](C(=O)O)N
|
| InChi Key |
CVNFYQCHAWFYQI-ZSCHJXSPSA-N
|
| InChi Code |
InChI=1S/C13H11ClN2O2.C6H14N2O2/c1-8-10(14)5-2-6-11(8)16-12-9(13(17)18)4-3-7-15-12;7-4-2-1-3-5(8)6(9)10/h2-7H,1H3,(H,15,16)(H,17,18);5H,1-4,7-8H2,(H,9,10)/t;5-/m.0/s1
|
| Chemical Name |
2-(3-chloro-2-methylanilino)pyridine-3-carboxylic acid;(2S)-2,6-diaminohexanoic acid
|
| Synonyms |
Clonixin lysine salt Dolalgial Lysine clonixinate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4457 mL | 12.2285 mL | 24.4571 mL | |
| 5 mM | 0.4891 mL | 2.4457 mL | 4.8914 mL | |
| 10 mM | 0.2446 mL | 1.2229 mL | 2.4457 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA